Travere Therapeutics, Inc. carried $311.7M in long-term debt against $93.0M in cash and equivalents at the end of fiscal year 2025. Long-term debt rose 0.5% from the prior fiscal year. The table below carries 15 fiscal years, from 2012 to 2025, and the quarters Travere Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
TVTX Debt & Cash by Fiscal Year
Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-Q | FY2310-K | FY22Filing | FY2110-K | FY2010-K | FY1910-K | FY18Filing | FY17Filing | FY1610-K | FY15Filing | FY1410-K | FY1310-K | FY1210-K | FY1210-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $311.7M+0.5% | $310.3M-17.7% | $377.3M+0.5% | $375.5M+65.7% | $226.6M+5.2% | $215.3M+5.1% | $204.9M+5.0% | $195.1M+332.8% | $45.1M+1.5% | $44.4M+1.5% | $43.8M+1.1% | $43.3M | N/A | N/A | N/A |
| Cash & Equivalents | $93.0M+58.9% | $58.5M+0.6% | $58.2M-5.7% | $61.7M-62.8% | $165.8M+95.5% | $84.8M+35.8% | $62.4M-39.3% | $102.9M+3.5% | $99.4M+142.4% | $41.0M+8.5% | $37.8M+107.7% | $18.2M+203.6% | $6.0M+54418.2% | $11K | $1K |
TVTX Debt & Cash by Quarter
Figures are in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | N/A | N/A | N/A | $311.7M+0.5% | $311.4M+0.5% | $311.0M-17.7% | $310.7M-17.7% | $310.3M-17.7% | $310.0M-17.7% | $378.1M+0.5% | $377.7M+0.5% | $377.3M+0.5% |
| Cash & Equivalents | $123.5M+11.4% | $117.7M+56.7% | $78.4M+26.6% | $93.0M+58.9% | $110.9M+204.7% | $75.2M+132.7% | $61.9M+43.1% | $58.5M+0.6% | $36.4M-74.8% | $32.3M-54.4% | $43.3M-73.2% | $58.2M-5.7% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Travere Therapeutics, Inc. financials
Frequently Asked Questions
Travere Therapeutics, Inc. carried $311.7M in long-term debt against $93.0M in cash and equivalents at the end of fiscal year 2025.
Travere Therapeutics, Inc. (TVTX) long-term debt rose by 0.5% year over year, from $310.3M to $311.7M in fiscal year 2025.
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Travere Therapeutics, Inc. (TVTX) reported on that line in every period on record.